| Pharmaceutical Information |
| Drug Name |
Naldemedine |
| Drug ID |
BADD_D02481 |
| Description |
Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of [DB00704] to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation. |
| Indications and Usage |
For the treatment of opioid-induced constipation [FDA Label]. |
| Marketing Status |
approved; investigational |
| ATC Code |
A06AH05 |
| DrugBank ID |
DB11691
|
| KEGG ID |
D10188
|
| MeSH ID |
C000620491
|
| PubChem ID |
54732242
|
| TTD Drug ID |
D0Q3PD
|
| NDC Product Code |
59385-041 |
| UNII |
03KSI6WLXH
|
| Synonyms |
naldemedine | S-297995 | Symproic |
|
| Chemical Information |
| Molecular Formula |
C32H34N4O6 |
| CAS Registry Number |
916072-89-4 |
| SMILES |
CC(C)(C1=NC(=NO1)C2=CC=CC=C2)NC(=O)C3=C(C4C56CCN(C(C5(C3)O)CC7=C6C(=C(C=C7)O)O4)
CC8CC8)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
